CUE vs PH · rev $9.3M vs P/E 28, rev $19.85B
Cue Biopharma (CUE) versus Parker-Hannifin Corporation (PH) — a side-by-side from cached financials, not a winner call.
Cue Biopharma (CUE) is a biotechnology company listed on US.
Parker-Hannifin Corporation (PH) is a specialty industrial machinery company listed on US.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
Latest reported PH revenue for 2025-06-30 was $19.85B. Net income was $3.53B. PH currently screens at market cap $91.89B and trailing P/E 27.7.
CUE currently screens at market cap $59.5M. PH currently screens at market cap $91.89B and trailing P/E 27.7.
Not investment advice. Open the CUE and PH stock pages for the full models.
Not investment advice.